Development of KSHV vaccine platforms and chimeric MHV68-K-K8.1 glycoprotein for evaluating the <i>in vivo</i> immunogenicity and efficacy of KSHV vaccine candidates.

ABSTRACT: Kaposi's sarcoma-associated herpesvirus (KSHV)/human herpesvirus 8 is an etiological agent of Kaposi's Sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Considering the high seroprevalence reaching up to 80% in sub-Saharan Africa, an effective vaccine is crucial for preventing KSHV infection. However, vaccine development has been limited due to the lack of an effective animal model that supports KSHV infection. Murine Herpesvirus 68 (MHV68), a natural mouse pathogen persisting lifelong post-infection, presents a promising model for KSHV infection. In this study, we developed KSHV vaccine and a chimeric MHV68 carrying the KSHV glycoprotein, serving as a surrogate challenge virus for testing KSHV vaccines in a mouse model. Among KSHV virion glycoproteins, K8.1 is the

SUBMITTER: Yang W-S 

PROVIDER: S-EPMC11633179 | biostudies-literature | 2024 Dec

REPOSITORIES: biostudies-literature